studies | A clearly stated aim | Inclusion of consecutive patients | Prospective data collection | Endpoints appropriate to the aim of the study | Unbiased assessment of the study endpoint | A follow-up period appropriate to the aims of study | Less than 5% loss to follow-up | Prospective calculation of the sample size | An adequate control group | Contemporary groups | Baseline equivalence of groups | Adequate statistical analyses | Total score |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abu-rajab 2006 [23] | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 22 |
Anis 2019 [24] | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 20 |
Bagsby 2016 [25] | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 1 | 2 | 2 | 21 |
Boyle 2017 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 2 | 2 | 2 | 2 | 20 |
Dodd 1990 [27] | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 22 |
Duffy 1998 [28] | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 2 | 2 | 2 | 2 | 20 |
Kamath 2011 [29] | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 2 | 2 | 2 | 2 | 21 |
Karachalios 2018 [30] | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 22 |
Miller 2017 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 22 |
Pap 2018 [32] | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 22 |
Pecina 2000 [33] | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 2 | 2 | 2 | 2 | 20 |
Prudhon 201 7[34] | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 20 |
Rand 1991 [35] | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 22 |
Rosenberg 1990 [36] | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 22 |
Sinicrope 2018 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 24 |